Boehringer Ingelheim's experimental anti-HIV drug is effective in some drug-resistant patients when used in combination with Abbott Laboratories' Norvir, U.S. regulatory staff said in documents released on Wednesday. Data for the Boehringer protease inhibitor, called Aptivus, previously known as tipranavir, "provide evidence of the additional antiviral effect over currently available antiretroviral regimens in a population which are 'heavily pretreated,' " Food and Drug Administration reviewers said. (Reuters)
Search
AI Powered
Human content,
AI powered search.
Latest Stories
Stay up to date with the latest in LGBTQ+ news with The Advocate’s email newsletter, in your inbox five days a week.
@ 2026 Equal Entertainment LLC.
All rights reserved
All rights reserved
By continuing to use our site, you agree to our Privacy Policy and Terms of Use.
The Latest
Support Independent Journalism
LGBTQ+ stories deserve to be told.
Your membership powers The Advocate's original reporting—stories that inform, protect, and celebrate our community.
Become a Member
FOR AS LITTLE AS $5. CANCEL ANYTIME.
More For You
Most Popular
@ 2026 Equal Entertainment LLC. All Rights reserved















